View Older Stories View More Recent Stories
-
Boston Scientific (BSX) Tops Q1 EPS by 8c, Beats on Revenue; Offers FY25 EPS Guidance
-
TD Cowen: 'Boston Scientific (BSX) Remains a Best Idea'
-
Needham Upgrades Boston Scientific (BSX) to Buy
-
RBC Capital on Boston Scientific (BSX): 'We See Room for a Beat and Raise'
-
RBC Capital Assesses U.S. Tariff Impact Across Industries
-
RBC Capital on Boston Scientific (BSX): 'Strong Near-Term Trends With Visibility On Growth Durability'
-
RBC Capital: 'Opportunities Across MedTech Stocks'
-
Jefferies Reiterates Hold Rating on Edwards Lifesciences (EW)
-
Boston Scientific (BSX) announces agreement to acquire SoniVie Ltd.
-
Boston Scientific announces board member Charles Dockendorff's departure
-
Boston Scientific (BSX) PT Raised to $120 at Stifel
-
Raymond James is very bullish on this MedTech stock. Here's why
-
Boston Scientific (BSX) PT Raised to $116 at RBC; 'Solid PFA & Broad Portfolio Momentum Offer Room for 2025 Upside'
-
Boston Scientific (BSX) PT Raised to $120 at Truist; 'We Think '25 Guide Has Room for Upside'
-
Boston Scientific (BSX) PT Raised to $130 at Mizuho
-
Boston Scientific (BSX) PT Raised to $117 at Canaccord Genuity
-
Needham Reiterates Hold Rating on Boston Scientific (BSX)
-
Boston Scientific (BSX) PT Raised to $121 at Bernstein, Citing 'Remarkable Organic Growth'
-
Boston Scientific (BSX) PT Raised to $120 at Jefferies
-
Boston Scientific (BSX) PT Raised to $122 at Citi
-
Boston Scientific (BSX) PT Raised to $120 at BTIG
-
Boston Scientific (BSX) PT Raised to $115 at BofA Securities
-
Boston Scientific (BSX) Tops Q4 EPS by 4c, Beats on Revenue; Offers FY25 EPS Guidance
-
MedTech sector outlook for 2025: Truist Securities
-
TD Cowen on Boston Scientific (BSX): 'Data Reinforce Strong Growth Outlooks for FARAPULSE and WATCHMAN'
-
RBC Capital on Boston Scientific (BSX): 'Consistent Top Performer That Isn't Slowing Down'
-
Citi Reiterates Buy Rating on Boston Scientific (BSX)
-
Deutsche Bank Upgrades Boston Scientific (BSX) to Buy
-
Truist Securities Reiterates Buy Rating on Boston Scientific (BSX) Following Bolt Medical Acquisition
-
BTIG Reiterates Buy Rating on Boston Scientific (BSX) following Bolt Medical deal
-
Piper Sandler Reiterates Overweight Rating on Boston Scientific (BSX): 'We Expect the Stock Will Grind Higher'
-
Boston Scientific (BSX) to Acquire Bolt Medical
-
Boston Scientific (BSX) PT Raised to $101 at BTIG
-
Insulet Corporation (PODD) PT Raised to $300 at BTIG
-
Truist Securities Names Boston Scientific (BSX) as 'Favorite 2025 LGCP Pick'
-
Medical Technology and Devices: Piper Sandler Shares 'Quick Thoughts on HC Conference in Jan'
-
Boston Scientific (BSX) PT Raised to $110 at Truist Securities on Upside Potential
-
RBC's Best Picks For 2025 in Medical Supplies & Devices: 'Oasis of Opportunity Awaits as MedTech Momentum Continues'
-
Boston Scientific (BSX) Pacemakers May Need Early Replacement - FDA
-
TD Cowen on Boston Scientific (BSX): 'Next-Level Growth Plan Ready to Deliver Another Big Year'; Best Idea for 2025
-
RBC comments on medical devices sector ahead of EW's Investor Day
-
Is Trump 2.0 good or bad for healthcare stocks?
-
Needham Reiterates Hold Rating on Boston Scientific (BSX)
-
Boston Scientific (BSX) to Acquire Intera Oncology
-
TD Cowen Reiterates Buy Rating on Boston Scientific (BSX)
-
Boston Scientific (BSX) Closes Acquisition of Axonics (AXNX)
-
TD Cowen Reiterates Buy Rating on Boston Scientific (BSX)
-
Boston Scientific (BSX) to Acquire Cortex
-
Boston Scientific (BSX): ACURATE neo2 Aortic Valve System Data Presented at Late-Breaking Clinical Trial Session at TCT 2024
-
Medtronic (MDT) Gains, Boston Scientific (BSX) Declines

